Sino Biopharma Signs US$358 Million Drug Licensing Deal

On 6 November, Sino Biopharmaceutical announced a deal with Boehringer Ingelheim worth US$358 million upfront, with potential milestone and option payments of up to US$7 billion, plus royalties. HPC can support pharmaceutical investment research and strategic introductions.

If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.